Frontlight ResearchEarly access
Melanoma trials in France
42 of 61 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleA Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Where
- Paris, Villejuif
- Age
- 6 months to 17 years
- People
- 370 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00 - Phase 4Active, not recruitingDabrafenib and/or Trametinib Rollover Study
- Where
- Lyon, Nantes, Paris, Villejuif
- Age
- 18 years to 100 years
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - Phase 1Taking peoplePhase 1 Study of PF-08046033 in Advanced Solid Tumors
- Where
- Toulouse, Villejuif
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Pfizer
See details and how to joinNCT07519655 - Phase 2Taking peopleA Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Where
- Dijon, Paris, Pierre-Bénite, Villejuif
- Age
- 18 years and over
- People
- 254 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07492680 - Phase 3Taking peopleSUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Where
- Lille, Paris, Villejuif
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Immatics US, Inc.
See details and how to joinNCT06743126 · EU 2024-517062-42-00 - Phase 2Not yet taking people in FranceDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Angers, Dijon, Lyon, Marseille, Paris, Poitiers, Saint-Herblain Cedex
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - No phaseNot yet taking people in FranceDevelopment of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D System.
- Where
- Marseille
- Age
- 18 years and over
- People
- 1,000
- Run by
- Assistance Publique Hopitaux De Marseille
See details and how to joinNCT06999499 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Besancon Cedex, Bordeaux, Bordeaux Cedex, Dijon, Lyon, Montpellier Cedex 5, Paris, Rennes Cedex, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 2Not yet taking people in FranceNeoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study.
- Where
- Besancon Cedex, Dijon
- Age
- 18 years and over
- People
- 19
- Run by
- Centre Hospitalier Universitaire de Besancon
See details and how to joinNCT07883759 · EU 2024-519573-19-00 - Phase 2/3Taking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Bayonne, Bordeaux, Boulogne-Billancourt, Grenoble Cedex 9, Lille, Marseille, Nice, Paris Cedex 18, Pierre-Bénite, Rouen Cedex, Saint-Herblain Cedex, Strasbourg
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - Phase 3Taking peopleStudy to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Where
- Marseille, Nantes, Paris
- Age
- 18 years to 70 years
- People
- 670 worldwide
- Run by
- Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00 - Phase 1Taking peopleA Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Where
- Bordeaux, Caen, Lille, Lyon, Marseille, Nantes, Nice, Paris, Pierre-Bénite, Poitiers, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT04913285 - Phase 1/2Taking peopleA Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Where
- Villejuif
- Age
- 18 years and over
- People
- 366 worldwide
- Run by
- Marengo Therapeutics, Inc.
See details and how to joinNCT05592626 · EU 2023-505334-10-01 - Phase 2Taking peopleClinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
- Where
- Bordeaux, Lyon, Marseille, Nice Cedex 2, Paris, Rennes Cedex, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 51
- Run by
- UNICANCER
See details and how to joinNCT07340619 · EU 2025-521982-29-00 - Phase 2Taking peopleNeo-adjuvant Immunotherapy in Patients With Localized Melanoma
- Where
- Bordeaux, Lyon, Marseille, Paris, Villejuif
- Age
- 18 years and over
- People
- 50
- Run by
- UNICANCER
See details and how to joinNCT07230613 - Phase 3Taking peopleVO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
- Where
- Bordeaux Cedex, Lille, Marseille, Nice, Paris, Pierre-Bénite, Villejuif
- Age
- 12 years and over
- People
- 400 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06264180 · EU 2023-508612-29-00 - Phase 1/2Taking peopleA phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours
- Where
- Lyon, Villejuif
- Age
- 18 years and over
- People
- 48 worldwide
- Run by
- Apmonia Therapeutics
See details and how to join2025-521164-36-00 - Phase 3Taking peopleAdjuvant Tebentafusp in High Risk Ocular Melanoma
- Where
- Clermont Ferrand Cedex1, Nice Cedex 2, Paris, Rennes Cedex
- Age
- 18 years and over
- People
- 290 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT06246149 · EU 2023-510333-28-00 - No phaseTaking peopleEvaluation of Skin Tests in Biotherapy Allergies
- Where
- Angers
- Age
- 18 years and over
- People
- 70
- Run by
- University Hospital, Angers
See details and how to joinNCT06971848 - No phaseTaking peopleAlpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
- Where
- Grenoble, Lyon
- Age
- 18 years and over
- People
- 80
- Run by
- Alpha Tau Medical LTD.
See details and how to joinNCT04068155 - No phaseTaking peopleResearch of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
- Where
- Toulouse
- Age
- 18 years and over
- People
- 450
- Run by
- Institut Claudius Regaud
See details and how to joinNCT06967961 - Phase 3Taking peopleNeoadjuvant Darovasertib in Primary Uveal Melanoma
- Where
- Nice, Paris
- Age
- 18 years and over
- People
- 520 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07015190 · EU 2025-522387-32-00 - Phase 1/2Not yet taking people in FranceA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- Where
- Lille, Paris, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06413680 · EU 2025-523399-22-00 - Phase 2/3Not yet taking people in FranceA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Where
- Lyon, Paris
- Age
- 18 years and over
- People
- 280 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06581406 · EU 2023-508784-68-00